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Abstract: Free radicals play a key role in many physiological decisions in cells. Since free 
radicals are toxic to cellular components, it is known that they cause DNA damage, 
contribute to DNA instability and mutation and thus favor carcinogenesis. However, 
nowadays it is assumed that free radicals play a further complex role in cancer. Low levels 
of free radicals and steady state levels of antioxidant enzymes are responsible for the fine 
tuning of redox status inside cells. A change in redox state is a way to modify the 
physiological status of the cell, in fact, a more reduced status is found in resting cells while 
a more oxidative status is associated with proliferative cells. The mechanisms by which 
redox status can change the proliferative activity of cancer cells are related to 
transcriptional and posttranscriptional modifications of proteins that play a critical role in 
cell cycle control. Since cancer cells show higher levels of free radicals compared with 
their normal counterparts, it is believed that the anti-oxidative stress mechanism is also 
increased in cancer cells. In fact, the levels of some of the most important antioxidant 
enzymes are elevated in advanced status of some types of tumors. Anti-cancer treatment is 
compromised by survival mechanisms in cancer cells and collateral damage in normal  
non-pathological tissues. Though some resistance mechanisms have been described, they 
do not yet explain why treatment of cancer fails in several tumors. Given that some 
antitumoral treatments are based on the generation of free radicals, we will discuss in this 
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review the possible role of antioxidant enzymes in the survival mechanism in cancer cells 
and then, its participation in the failure of cancer treatments. 
Keywords: redox control; proliferation; survival 
 
Abreviations 
γ-GCS, γ-Glutamyl Cysteine Synthase; OH, Hydroxyl radical; 8OHdG, 8-hydroxy-2'-deoxyguanosine; 
ASK, Apoptosis Signal-regulated kinase 1; cGMP, cyclic Guanosyl Monophospate; CuZnSOD 
(SOD1), Cu, Zn-dependent Cytoplasmic Superoxide Dismutase; CYP, Cytochrome P450; EGF, Epithelial 
Growth Factor; EPA, Eicosapentaenoic acid; GC, Guanylate Cyclase; GSH, Glutathione; GSTs, 
Glutathione S-Transferases; HO-1, Heme Oxygenase 1; HPLC, High Pressure (performance) Liquid 
Chromatography; HSF1, Heat Shock Factor 1; MAPKs, Mitogen-activated Protein Kinases; MnSOD 
(SOD2), Manganese-dependent Mitochondrial Superoxide Dismutase; MRP1, Multidrug Resistant 
Protein-1; mTOR, mammalian target of Rapamycin; NER, Nucleotide Excision Repair; NES, Nuclear 
Export Signal; NFκB, Nuclear factor-κB; NOS, Nitric Oxide Synthase; O2•−, Superoxide radical; 
OGG1, 8-oxo-guanine DNA Glycosylase; OxyR, Hydrogen peroxide-inducible genes activator; 
PARP, polyadenosine-5'-dephosphate ribose polymerase; PDGF, Platelet-derived Growth Factor; 
PDGFR, Platelet-derived Growth Factor Receptor; PI3K, Phosphatidyl Inositol 3-Kinase; RNS, 
Reactive Nitrogen Species; ROS, Reactive Oxygen Species; RPTKs Receptor-coupled Protein Tyrosine 
Kinases; SAPK/JNK, Stress-activated Protein Kinases; SNPs, Single Nucleotide Polymorphism; TNF, 
Tumor Necrosis Factor; TRAF1, TNF Receptor-associated Factor 1; Trx, Thioredoxin; VEGF, 
Vascular Endothelial Growth Factor; VSMCs, Vascular Smooth Muscle cells; XOR, Hypoxanthine-
Xanthine Oxidoreductase; Yap1, Yeast-activating Protein 1. 
1. Introduction 
Cancer cells are continuously dividing and avoiding any control on their cell cycle. Therefore 
seeking those mechanisms altered and also, molecules able to control its progression has attracted the 
attention of scientists. It is reasonable to admit that there is not only one way to explain why cancer 
cells behave as they do. Moreover, cancer cells show a complete alteration of their physiology, 
metabolism, genome and proteome but, that only partially explains their behavior. Once we admit that 
not a few mutations, proteins, pathways or phenomenons are changed and also, that those mutations, 
proteins, pathways or facts can change in a precise cell type but cannot be changed in another cell 
types, then we will be able to understand at least in part what a cancer cell represents. Several changes, 
endogenous and exogenous, alter the physiology of normal cells and convert them in a way difficult to 
understand and manage. 
Then, cancer must be considered a complex and multifaceted illness that affects different patients in 
various ways. Cancer evidences the imbalance of control mechanisms that assure the proper 
functioning of cells. Looking inside the complex machinery that assures our body functioning, it is not 
difficult to imagine that simple changes can promote imbalances and a great disaster. Not only 
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mutations, but also DNA repair mechanisms, must protect our DNA from damage. Not only growth 
factor signaling, but also feedback mechanisms, protect us from continuous stimulation of cell growth. 
In the same way, not only oxidative phosphorylation, but also antioxidant mechanisms protect our 
macromolecules from the damage caused by toxic byproducts. 
Nowadays, the search for the alteration of complete pathways and personalized therapies seem to be 
the most appropriate way to fight against this disease. Cancer is a leading cause of death worldwide 
and kills more than a 500,000 persons year only in America, below only heart diseases. It accounted 
for 7.9 million deaths worldwide (around 13% of all deaths) in 2007. Although anyone can develop 
cancer, about 78% of all cases are diagnosed in people 55 years old and older, but the most frequent 
types differ between men and women. Lung, stomach, liver, colon and breast cancer cause the most 
cancer deaths each year. Deaths from cancer worldwide are projected to continue rising, with an 
estimated 12 million deaths per year expected by 2030. 
Tumor formation is a multistage process involving a series of events which include the accumulation 
of genetic and epigenetic alterations leading to the progressive transformation of a normal cell into a 
malignant one. Modifications may be started by external agents and inherited genetic factors. Cancer 
cells acquire abilities that normal cells do not have, including survival mechanisms which enable them 
to evade cell death [1]. Despite the development of new therapies, cancer is still the second leading 
cause of death in Western countries. Several types of tumors develop a resistance to avoid cell death 
induced by conventional treatments. 
A free radical is defined as an atom or a molecule with one or more unpaired electrons in an 
outermost valence shell. ROS include O2-derived free radicals, in fact O2 is a biradical but also,  
non-radical derivatives of O2 such as hydrogen peroxide H2O2 exist. ROS have been normally 
recognized by radiation chemists as products generated by the radiolysis of water, and today this is the 
principal mechanism employed by radiologists to treat cancer [2]. Endogenous radical production can 
occur and approximately 2% of the total mitochondrial O2 consumption results in O2− production [3], 
in addition to the ROS formed as byproducts of certain enzymatic reactions [4,5]. For this reason cells 
must maintain an endogenous antioxidant capacity based on water or lipid soluble compounds and 
enzymatic systems that remove ROS but also, may include proteases specialized in the removal of 
oxidatively modified proteins, DNA or lipids [6]. 
An increase in free radicals, through an increase in production or a defect in removal, causes DNA, 
protein or lipid damage that can play a critical role in carcinogenesis but also, a delicate change in 
redox conditions can play a role in tumor progression by affecting cell growth or survival. In this 
review, we will go over the main points that show the critical role of free radicals, antioxidants and 
redox balance in cell growth and survival. The review will focus attention on recent reports and the 
important role, not only as carcinogens, but also as cell signaling molecules of oxygen and nitrogen 
radicals. Also, the main role of antioxidant enzymes in cancer progression as well as its particular 
importance in cell survival in non-pathological and pathological conditions will be discussed below. 
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2. Free Radicals, Oxidants and Antioxidants 
2.1. Importance and Source of Free Radicals in Living Cells 
Several decades ago an inverse correlation between the rate of oxygen consumption and the 
longevity of mammals was proposed. Although no longer accepted, this “rate-of-living” theory of 
aging highlighted the importance of oxygen metabolism in eukaryotic cells [7]. Later on, more than  
five decades ago, Harman proposed the free radical theory which states that oxygen and nitrogen free 
radical species (ROS/RNS) are formed endogenously, being hydroxyl (•OH) and peroxyl radicals 
(•O2H) the major “culprits” of biological oxidative damage. Furthermore the free radical theory relates 
them directly with the aging process [8]. Earlier discoveries pointed out the importance of oxygen 
toxicity by demonstrating the inhibition of several enzymes [9]. However, initially this theory did not 
attract much of attention from scientists, until a parallel was demonstrated between the effects of O2 
and those of ionizing radiation, leading to the discovery that oxygen free radicals actually occur in 
biological systems and are responsible for most of the damaging effects observed [10,11]. Interestingly, 
now it is perfectly established that oxygen radicals are also derived from normal cell metabolism as a 
side product. 
Apparently in vivo ROS/RNS can be derived from many different sources, including auto-oxidation, 
photochemical or enzymatic reactions and may involve both endogenous compounds and various 
xenobiotics. Among enzymes shown to be capable of generating ROS, cytochromes P450, oxidases, 
peroxidases, lipoxygenases and dehydrogenases are included [12]. The involvement of xenobiotics can 
be particularly important in determining the extent of ROS generated by these enzymes, relating them 
directly with mutagenesis (see below). However, among all the potential sites of ROS production in vivo, 
the main source is the electron transport chains, especially those present in bacterial membranes or in 
the endoplasmic reticulum and mitochondria in eukaryotic cells. Thereby this latter organelle is the 
main ROS source [13–16], which actually prompted Harman in 1972 to propose a slight “fine tuning” 
of the free radical theory, focusing the attention on mitochondria [17]. Based on several reports it has 
been suggested that even at physiological O2 concentrations, occasional electron leakage occurs along 
mitochondrial respiratory chain-especially at earlier components such as respiratory complex I, leading 
to a roughly 1–3% of O2•− formation. Eventually this amount would increase at elevated O2 
concentrations [18]. Although the quantity produced in vivo under both normal and pathologic 
conditions is unknown, some authors claim that the actual production of radicals by intact 
mitochondria in non-pathologic tissues is likely to be less than 2% under normoxic conditions. However, 
substantially more may be produced under damaging conditions or in the presence of numerous 
xenobiotics and carcinogens. 
Based on this evidence, under basal conditions superoxide radical (O2•−) and H2O2—which is not a 
free radical per se—account for the majority of ROS generated inside cells. Most authors agree that, 
unless some cellular defensive mechanism(s) comes to the rescue, mitochondrial activity would 
eventually lead to a rise in intracellular O2•− concentration over a threshold, thus compromising cell 
survival [18]. Remarkably O2•− when compared to other free radicals, seems to be innocuous from the 
reactivity point of view. Nonetheless its protonated form, HO2•−, is more reactive and can cross cell 
membranes as H2O2 which is considerably more dangerous. However, again H2O2 is not highly 
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reactive from the chemical point of view but it is well demonstrated that indirectly it can lead to the 
formation of other highly-damaging free radicals through the well-known Haber-Weiss or more frequently 
the iron-catalyzed Fenton reactions. The question is how cells counteract this continuous “radical” 
challenge. For this purpose, several antioxidant mechanisms, either endogenous enzymatic and  
non-enzymatic as well as exogenous small molecular weight antioxidants from diet, appeared during 
evolution as essential pieces to prevent ROS/RNS-mediated cell death. 
2.2. ROS/RNS and Oxidative Stress 
Conceptually speaking, once it was assumed that endogenously formed radicals from normal 
metabolic processes could play a role in aging an in many other diseases and that, fortunately, there is 
a set of intracellular antioxidant mechanisms confronting them inside cells, Sies first introduced the 
term “oxidative stress” almost 30 years ago [19]. Later in 1991 he exactly defined the term as “a 
disturbance in the prooxidant-antioxidant balance in favour of the former, leading to potential damage” 
which is usually called oxidative damage. Consequently, at least in a healthy situation, there must be a 
necessary balance between production of ROS/RNS and their clearance by antioxidants. Several 
situations could then contribute to oxidative stress, namely (i) diminished antioxidants, e.g., reduction 
in antioxidant defenses like antioxidant enzymes; (ii) increased production of ROS/RNS, e.g., 
elevation of O2 or presence of radical-forming xenobiotics, toxins, etc. Accordingly the term 
“mitochondrial oxidative stress theory of aging” it is now commonly accepted to redefine the free 
radical theory to explain aging. Moreover, several lines of evidence strongly support the instrumental 
role of oxidative stress, not only in aging but also in many other diseases, including cancer [20–22]. 
Nevertheless, along the evolutionary process, eukaryotic cells developed a reduction-oxidation (redox) 
regulatory system involving basal levels of free radicals in such way that those molecules became 
important signaling effectors as a basic redox control tool, joining the two other common mechanism 
of cell signaling, i.e., high-energy chemicals and transmembrane ion-gating mechanisms [23,24]. 
3. Cell Damage by Free Radicals in Normal Tissues 
3.1. Basal Levels of Free Radicals 
Thousands of studies have already shown that free radicals per se, due to their reactive chemical 
nature can harm multiple intracellular targets, including major macromolecules (i.e., proteins, DNA or 
lipids). Additionally, free radical species indirectly formed by the action of xenobiotics, pollutants or 
other carcinogens are indeed responsible for oxidative damage of macromolecules that finally ends up 
in nucleotide mutations in DNA. Moreover, during the past two decades extensive research has 
revealed the role of oxidative stress in causing chronic inflammation which is directly linked to 
chronic diseases like cancer [25]. In this way Halliwell has elegantly addressed how redox control in 
an increasing oxidative situation might induce one of the following outcomes when cells move 
progressively from a highly reduced to a highly oxidized intracellular environment: (1) increased 
proliferation; (2) adaptation by up-regulation of antioxidant defense; (3) cell injury; (4) senescence;  
(5) cell death [26]. 
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Usually resting cells show a highly reduced intracellular environment, rich in reduced glutathione 
(GSH) with high concentrations in other endogenous antioxidants like ascorbate and with a ratio GSH: 
GSSG over 99% [18]. However at this stage, some degree of oxidized microenvironments  
(i.e., endoplasmic reticulum) is needed, which allow folding of newly formed proteins to form 
disulfide bonds [27]. As it will be discussed below, several transcription factors are controlled by 
redox signaling. Consequently, mitochondrial or NAD(P)H oxidase ROS production, usually through 
final generation of low, non-toxic, basal levels of H2O2 regulates several transcription factors that 
stimulate the proliferation of several cell types in culture [28,29]. Furthermore, exogenously added 
hydrogen peroxide is able to induce cell proliferation in certain cell types [30–32]. Likewise contact 
growth inhibition observed in cultured cells is due to a decrease of intracellular ROS production [33]. 
If either external source of ROS persists or there is an overproduction of radicals inside cells, oxidative 
damage eventually rise and cells enter into next stage of adaptation, which includes, among others,  
up-regulation of antioxidant enzymes. This process may also occur in early stages of tumor 
development and it also appears during ROS generating treatments like radiation or chemotherapy, 
indicating a critical role of antioxidant enzymes, specially MnSOD, in such radiation-induced 
adaptation [34–36]. Finally in a last stage, along with an increase in oxidative stress, cells would enter 
into a cell death-inducing situation. 
While redox control of cell proliferation has only received attention in the last few years, the 
ROS/RNS-mediated damage is much better known. When chemical or physical stimulus continues, 
cell injury and/or senescence occur. In a certain range of oxidative stress there is still a reversible 
response and cell might return situation to normal but once a critical oxidative damage is reached, cell 
death becomes inevitable. Thus apoptosis is usually triggered by oxidizing agents and subsequently 
antioxidants will shut down free radical-mediated oxidation. Among other apoptosis-related factors, 
caspases are notably dependent on certain sulfhydryl residues. Consequently, if intracellular environment 
is too oxidized, caspases do not work properly and apoptosis is blocked [37]. This helps to explain the 
pro-apoptotic effects of some antioxidants, especially in combination with other agents [38]. 
3.2. DNA Damage Caused by Free Radicals and Its Role in Carcinogenesis 
ROS/RNS can be harmful to most macromolecules, including lipids, proteins or DNA [18]. When 
oxidative stress occurs, it may be difficult to establish which of these molecules reacts first with 
ROS/RNS. However oxidative stress itself would accelerate the normal spontaneous chemical 
decomposition suffered by DNA bases. Similarly, it is widely reported that DNA damage occurs 
continuously, measured as 8-hydroxy-2'-deoxyguanosine (8OHdG) or as other base modifications [39,40]. 
These modifications usually can be easily monitored by quantitative HPLC assays [41] and they can 
anticipate the presence of mutations as Cheng et al. demonstrated. Thus, 8OHdG causes G→T and 
A→C substitutions [42] and its presence has been associated with several types of tumors [43–46] but 
not with others [47]. Also, ROS/RNS generated by UV radiation induce tandem mutations in p53 in 
skin cancers [48]. From all ROS generated inside cells, only the highly reactive •OH has energy to 
modify DNA [49] while other can participate through metal-catalyzed Fenton reactions giving rise to 
•OH. Other useful biomarkers of ROS/RNS-mediated damage in cancer samples are lipid peroxidation, 
specially assayed as the presence of isoprostanes/isofurans or as aldehydes [50–52] as well as protein 
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oxidative damage, measured as nitration or nitrosation of certain residues like tyrosine or as carbonyl 
content [52,53]. 
Among exogenous sources of reactive oxygen species, ionizing radiation, environmental agents and 
therapeutic agents can be included. All of them are able to act as human carcionogens. Ionizing 
radiation has been found to induce cancer in several species and affects at all stages of carcinogenesis. 
Inflammatory cells including neutrophils, eosinophils and macrophages contribute to the cellular 
burden of ROS. Phagocytes produce ROS through NADPH oxidase, the enzyme that catalyzes the 
single electron reduction of oxygen to O2•−. ROS generated by this mechanism play an important role 
in cellular defense by killing bacteria but have also been involved in the development of tumors [54]. In 
fact, it is considered that infection and chronic inflammation can contribute to 1 out of 4 of all cancers 
diagnosed [55]. A sustained inflammatory microenvironment provides a constant supply of ROS/RNS 
that could contribute with cytokines, chemokines and growth factors, in altering cellular homeostasis 
and lead to genomic instability and to raise the risk of cancer development. In vitro and in vivo 
evidences implicate inflammation in altering multiple pathways related to cancer progression [56]. 
Thus, mutation studies have suggested that chronic oxidative stress is associated with carcinogenesis. 
For example, ulcerative colitis is linked with higher incidence of colorectal cancer or chronic gastritis 
due to infection with Helicobacter pilori and therefore might be responsible of higher incidence of 
gastric cancer [57]. 
Oxidative DNA damage is a major source of mutation and its frequency is estimated at  
104 lesions/cell/day [58]. The most extensively studied oxidative DNA damage is the rate of  
8-hydroxydeoxy guanosine (8-OHdG), which is mutagenic in bacteria and mammalian cells. 8-OHdG 
is elevated in tumor cells and in animal models of cancer. Its stable conformation can pair with both 
cytosine and adenine. G:C or A:T transversion caused by 8-OHdG in the DNA template is commonly 
found in mutated oncogenes or tumor suppression genes [42]. During replication, ROS can also react 
with dGTP to form 8-OHdG which is also able to be incorporated into DNA opposite a template 
strand. In fact, 8-OHdG has been widely used as a biomarker of DNA oxidative damage and it is 
useful to evaluate the level of oxidative stress in a particular system. Also, RNS produce during 
chronic inflammation cause 8-nitroguanine which has been considered a mutagenic DNA lesion and 
leads to G→T transversions [54]. 
In addition to a promotion of mutagenesis and initiation of tumor progression some polymorphisms 
have been reported in oxidative-stress related genes, including carcinogen metabolizing genes which 
also contribute to their role in carcinogenesis. About 10 million polymorphisms (SNPs) exist in the 
human genome, and while some of these variations are silenced, a small proportion are found in coding 
or regulatory sequences and imply phenotypic changes. Among others oxidative stress related genes or 
DNA repair genes, including carcinogen metabolizing genes, present genetic polymorphisms that may 
explain individual differences in their expression or activity and its role in carcinogenesis. Cytochrome 
P450 (CYP) gene family, a phase I detoxifying enzyme, or glutathione-S-transferase, an element of 
phase II metabolic enzymes and an antioxidant enzyme, which are in charge of detoxifying 
environmental carcinogens, are reported to be polymorphic and those polymorphisms are related to 
human cancers [55,56]. Also, polymorphisms in DNA repair genes which are implicated in 8-OHdG, 
including base excision repair (BER) enzymes or 8-oxo-guanine DNA glucosylase (OGG1) in addition 
to nucleotide excision repair (NER) can contribute to its role in carcinogenesis. In fact, epidemiological 
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studies investigating the association between SNPs of OGG1 have related the variant allele to a 
significantly increased risk of human cancers including lung, esophageal, prostate or gastric cancer [20,57]. 
ROS/RNS may have a triggering effect in cell damage. It has been suggested that tumors are in a 
“pro-oxidant” state generating more free radicals, which is usually not accompanied by up-regulation 
of DNA repair mechanisms. According to current knowledge, ROS/RNS can participate at multiple 
levels in carcinogenesis, either by direct effects on DNA or by modulating signaling pathways leading 
to increase in cell proliferation. Nonetheless direct role of ROS/RNS in carcinogenesis is mostly 
related to initiation and promotion, whereas rest of tumor stages can be indirectly related to free 
radicals through the chronic inflammation-related deregulation of cytokines or other factors released 
by macrophages [58]. 
4. Redox Control of Cell Growth 
4.1. ROS/RNS as Cell Signaling Molecules 
It has been historically assumed that ROS are tumor initiators simply by inducing genomic 
instability. However in 1995 Sundaresan et al. [59] showed that the stimulation of rat vascular smooth 
muscle cells (VSMCs) by platelet-derived growth factor (PDGF) transiently increased the intracellular 
concentration of H2O2, suggesting that H2O2 may act as a signaling transducer molecule, the role of 
oxygen-derived radicals in cellular signaling has been widely accepted. Since then, it is considered that 
ROS increase tumorigenesis not only by its carcinogenic or DNA damaging properties, but also by 
activating signaling pathways that regulate cellular proliferation, angiogenesis and metastasis [60]. 
These opening studies demonstrated that inhibiting the rise in ROS levels following ligand addition 
halts a variety of downstream pathways. Thus, depleting H2O2 by the addition of catalase to culture 
media, the ability of PDGF and also epithelial growth factor (EGF) to stimulate tyrosine 
phosphorylation does not occur [61]. However not only tyrosine kinases are regulated by ROS, also, 
several other molecules, related to cell cycle control or proliferation, are control by them. 
Different levels of ROS can activate different signaling pathways; therefore low or transient levels 
of ROS can activate proliferative signals, while high levels normally reduce cell proliferation by 
activating damage or cell death-related signals. It has been demonstrated that ROS activate kinases and 
inactivate phosphatases but also, they activate protein serine/threonine kinases, small G proteins or 
transcription factors signaling. All that pathways are in different ways altered in cancer cells which 
makes cancer cells to lack there control of proliferation and differentiation. 
4.2. Redox Control of EGF and PDGF Signaling 
The role of O2•− and H2O2 as mitogenic mediators is related to its ability to modulate receptor 
tyrosine kinases. Cell surface receptors for fibroblast growth factor (FGF), epidermal growth factor 
(EGF), vascular endothelial growth factor (VEGF), macrophage colony stimulating factor, hepatocyte 
growth factor, nerve growth factor or insulin-like growth factor cross the membrane with a single 
transmembrane pass, they have an extracellular ligand-binding domain and all them, have a 
cytoplasmic domain that upon activation transfer an ATP group to a selected tyrosine residues [62]. 
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Tyrosine residues sensitive to phosphorylation might be part of other receptors or downstream proteins 
involved in cellular signaling. 
EGF has four different receptors, ErbB1, ErbB3, ErbB4, which share more than 50% homology that 
when it binds to its ligand, is autophosphorylated and form dimers or oligomers. The activated receptor 
triggers intracellular signaling and promotes proliferation or cell migration [63,64]. Unexpectedly, the 
activation of human epidermoid carcinoma cells by EGF increases ROS production, in particular 
intracellular H2O2 level are increased after stimulation [65]. Molecular approaches showed that H2O2 
generation requires the receptor kinase activity of the receptor but also, that an increase in H2O2 is 
necessary but not sufficient for the increase in the steady-state level of protein tyrosine 
phosphorylation and that the inhibition of protein tyrosine phosphatase activity may be required. Later, 
it was demonstrated that H2O2 causes the oxidation of a sulfhydryl group at the active site of protein 
tyrosine phosphatases and that inhibition is reversed by the presence of antioxidants [66]. Redox-sensitive 
transactivation of EGFR occurs through a proximal tyrosine kinase, c-Src, which is shown to be 
activated by oxidative stress in cultured cardiac myocytes [67]. Similarly, the Src family of protein 
kinases, including phosphoinositol 3-kinase (PI3K), the GTPase-activating protein Ras, Src homology 
2 phosphatase 2 (SHP2) and phospholipase C-γ (PLC-γ), bind and phosphorylate seven  
auto-phosphorylation specific sites of the PDGF receptor [68,69]. The activation of PDGFR by 
binding PDGF homo or heterodimeric proteins increases O2•− production in human aortic smooth 
muscle cells [70]. Also, PDGF-BB was shown to generate O2•− in human lung fibroblast [71] and in 
bovine tracheal myocytes [72]. In both, the reported increase in O2•−, shortly after ligand binding, was 
not accompanied by NADH oxidase activation or H2O2 production. Moreover, cells overexpressing a 
mutant form of Ras protein failed to increase intracellular superoxide production in response to 
mitogenic stimuli. In that way, it was proposed that PDGF stimulated intracellular O2•− production via 
Ras-dependent activation of a O2•− generating oxidase/electron transferase and that, this mechanism 
may be a common signaling pathway in a number of RPTKs. PDGF receptor triggers intracellular 
signaling by recruiting members of the Src family of protein kinases. By expressing several mutants of 
PDFG receptor in HepG2 cells, it was shown that PDGF induced H2O2 production was blocked by 
PI3K inhibitors and by dominant negative mutants of Rac1 and Rho family GTPases [73]. More 
recently, the role of the cell adhesion receptor, syndecan-4, in regulating growth factor-induced ROS 
generation was studied. Rat embryo fibroblasts (REFs) overexpressing syndecan-4 exhibited increased 
ROS levels compared to control cells and a parallel enhancement of PDGF-induced MAP kinase 
activity suggesting that syndecan-4 regulates PDGF-induced MAP kinase activation by altering ROS 
generation too [74]. 
4.3. Redox Control of FGF and VEGF Signaling 
Fibroblast growth factors (FGF) are 20 different proteins that bind to four different receptors 
(FGFR-1 to FGFR-4) in order to achieve diverse effects in a variety of cell types. FGF receptor has 
also a three extracellular Ig-like domains, a transmembrane domain and an intracellular tyrosine kinase 
domain [75]. FGF binding promotes receptor dimerization and induces receptor kinase activation, 
recruiting FGF receptor stimulates several proteins, Grb2, SOS and SHP2. This recruitment promotes 
the activation of Ras and leads to signaling through ERK MAP kinase pathway. FGF factors have 
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several biological functions, including a potent role in growth and angiogenic activities which make 
them important players in wound healing [76] but they have also been reported to play a role in 
embryonic development [77]. H2O2 production after FGF-2 stimulation was demonstrated in 
chondrocytes [78] and it correlates with increased expression of c-fos. Antioxidants as N-acetylcysteine, 
inhibited FGF-2 induced c-fos mRNA, which confirms the role of ROS in mediating FGF-2 biological 
signals, at least in chondrocytes. Later on, FGF-2 was also demonstrated to increase shortly after 
binding to its receptor intracellular levels of O2•− via Ras-dependent activation of a O2•− generating 
oxidase/electron transferase [71]. 
Additionally ROS signaling increases the expression and levels of growth factors. That is the case 
of VEGF, which is a dimeric glycoprotein that interacts with three receptor kinases denoted VEGFR-1, -2 
and -3, generally expressed in endothelial cells. VEGF receptor stimulation activates several 
downstream signaling pathways which promote differentiation, migration, survival and permeability of 
endothelial cells. VEGF is the target of several antitumor agents since it is related to angiogenesis in 
tumors [79]. H2O2 was shown to increase VEGF gene transcription through activation of oxidative 
stress inducible transcription factors such as NFκB or AP-1 and this induction can be blocked by the 
employment of antioxidants [80]. 
4.4. ASK as a Redox Sensor 
Since ROS generation mediates the signaling pathways trigger by growth factors and tyrosine 
kinases or phosphatases, critical players in cell growth control, are regulated by redox reactions, it 
seems clear that ROS can be considered as secondary messengers in cell cycle regulation or at least, 
they play a key role, as other classical secondary messengers, in cell growth and death control. ROS 
can modulate protein function is by changing the oxidative state of cysteine residues present in the 
catalytic domain of proteins. Those modifications cause posttranscriptional changes that influence 
protein activity, turnover and subcellular trafficking but also, protein-protein interactions. Consequently, 
reactive modifications of cysteine in proteins implicated in cell fate is a transitory, specific and 
reversible signaling mechanism which resembles to other signaling molecules [81]. It is considered 
that almost 0.5% of all cysteine residues in the proteome are subjected to continuous and reversible 
oxidation-reduction and this redox control may regulate several aspects of the structure or function of 
eukaryotic cells [82]. In contrast to regulation by phosphorylation, ROS are small, diffusible and 
highly reactive molecules that can act at a distance and do not required the direct interaction of kinases 
and their substrate. However, oxidants also tend to be produced and metabolized locally [83]. 
Thus, some proteins, including apoptosis signal-regulated kinase 1 (ASK1), thioredoxin (Trx), 
peroxiredoxin family or calcineurin seem to be regulated by a redox mechanism [84–87]. In all that 
cases, oxidants may have direct effects on targets altering protein-protein interactions and regulating 
its enzymatic function. In the particular example of ASK1, a member of the family of mitogen-
activated protein kinase kinase kinases that is involved in the activation of stress activated protein 
kinases (SAPK/JNK kinases) and p38, it forms a complex with Trx which inhibits its activity. ASK1 is 
activated in cells treated with inflammatory cytokines or when cells are exposed to stressors such 
oxidative stress or ER stress. ROS increment after tumor necrosis factor (TNFα) stimulation promotes 
ASK1 activation and induces apoptosis [88]. By using a dominant negative mutant form of ASK1 cell 
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death induced by TNFα or oxidative stress is inhibited. Also, ROS such as H2O2 are the most potent 
activator the ASK1. In fact, anticancer drugs or irradiation trigger apoptosis in cancer cells through 
ROS-mediated ASK1 activation [89]. Trx was identified as a negative regulator of ASK1 which stays 
inactive in resting cells until treatment with TNFα, H2O2 or ROS donors when it is fully activated. Trx 
is a redox sensitive protein that possesses two cysteine residues within its active center. After oxidizing 
Trx, ASK1 switches from an inactive to an active form and activates the kinase signaling pathway. 
Thus, ASK1-Trx complex works as a redox sensor which communicates cellular redox state into 
kinase signaling pathways [88]. Also, other antioxidant proteins as peroxiredoxin family or superoxide 
dismutase 1 can regulate intracellular signaling molecules in a redox dependent manner [86,87]. 
4.5. Role of Cysteine Containing Proteins in Redox Sensing 
Although, it is considered that under physiological conditions cysteines might be in their protonated 
form (SH), some proteins in mammalian cells present oxidized cysteines. Thus, reactive cysteines are 
inactivated to a sulfenic ion when reacted with oxidative reactants. That change is reversible by the 
action of antioxidant proteins including Trx or glutaredoxins, however, when oxidative stress lasts 
reactive cysteines are converted to an irreversible oxidized status, a sulfinic ion. This scenario 
represents a reversible, specific and transient mechanism of cell signaling where persistent inactivation 
of proteins must exist while continued high levels of oxidative stress occurs. Proteins such as tyrosine 
phosphatases have a reactive cysteine in their active site. Since oxidative stress inactivates tyrosine 
phosphatases it is likely that persistent oxidation of these cysteine residues play a critical role in kinase 
pathways, which are one of the principal players in cellular growth control [24,81]. Also, covalent 
addition of glutathione to reactive cysteins may be a redox-dependent signaling mechanism. This 
mechanism has been reported after EGF stimulation, when transient glutathiolation of PTP-1B 
phosphatase has been found [90]. 
Thus, mild oxidative stress due to physiological unbalances is responsible for regulatory processes 
and represents the way by which a redox signal can be transduced within the cell. It was firstly 
evidenced in bacterial transcription factors. Thus OxyR is a good example of a redox sensitive 
prokaryotic transcription factor. Specific cysteine residues respond to H2O2, and the activation of 
OxyR involves the formation of a disulfide bond between Cys 199 and Cys 208 [91]. As a result, a 
change in DNA binding specificity occurs and the recruitment of RNA polymerase is the final result of 
OxyR redox changes. Later on it was found that a single thiol residue is critical for OxyR activity and 
this can be differently oxidized depending on the extent of redox unbalance and the nature of oxidizing 
molecules [92]. OxyR is a model of direct and highly inducible regulation that participates in survival 
of bacteria to adverse environments by modifying directly gene transcription after binding. In yeast, 
oxidative stress does not alter directly gene expression but instead it alters compartment location of 
transcription factors after oxidative stress. That is the case of yeast activating protein 1 (Yap 1), a 
functional homolog of the bacterial OxyR. Yap1 contains a noncanonical leucine-rich nuclear export 
signal (NES) embedded with the C-terminal cysteine-rich domain. Oxidative stress results in a 
conformational change that impedes Yap1 export and leads the accumulation of the protein in nucleus, 
which results in its enhanced nuclear concentration and binding affinity to DNA [93]. 
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Changes in intracellular redox state are also an additional signaling event in multicellular 
eukaryotes’ transcriptional activity. Some redox sensitive transcription factors have also been found in 
multicellular eukaryotes as p53, c-Jun/AP-1, nuclear factor-κB (NFκB) or heat shock factor 1 (HSF1). 
Some of these proteins are important regulators of cell cycle and apoptosis which control the 
transcription of critical proteins for cellular biology. Some reports indicate that cells treated with 
oxidants or oxidative-stress inducing agents are efficiently activated for nuclear translocation. 
However, the binding of transcription factors to DNA is allowed only upon reduction. Reduction of 
Cys 62 of p50 subunit of NFκB must be maintained to assure a correct binding to the promoter regions 
of its target genes [94]. The nucleus is in fact a very reducing compartment, in which GSH and Trx are 
present at high concentrations as well as redox sensitive factors such as Redox factor-1 (Ref-1). Trx in 
turn translocates into nucleus and modifies cysteine residues of sensitive transcription factors. Reducing 
nuclear environment not only activated gene transcription after redox modifications of transcription 
factors but also, protects DNA from oxidative damage [95]. 
Considering all of the above, the modification of the redox state of cysteine residues of specific,  
redox-sensitive proteins, including transcription factors, mitogen activated protein kinases or 
phosphatases, might be a widespread mechanism in the regulation of protein function, since growth 
factors stimulate ROS production to activate protein tyrosine kinases or inactivate protein tyrosine 
phosphatases through a reversible, specific and transient mechanism of cysteine modulation. 
Consequently, high levels of free radicals can contribute to cancer by DNA damage and mutation 
mechanism but also, by increasing cellular growth rates affecting to proteins which control growth, 
survival and differentiation of cancer cells. 
5. Antiproliferative and Pro-Apoptotic Activity of Antioxidants 
5.1. Diet Antioxidants and Cancer 
It seems obvious that if there is a redox control of cell growth, antioxidants might affect cellular 
growth either in physiological or pathological conditions. Two types of antioxidants must play a role 
in cancer, namely those exogenous antioxidants incorporated mostly by dietary intake but also, those 
endogenous antioxidants which contribute to control normal cellular redox status. 
From a basic point of view, antioxidants are efficient inhibitors of cell cycle progression and cell 
proliferation. Since early 90s, the antiproliferative activity of antioxidants such as N-acetylcysteine has 
been described [96] but it was not until recently, that the way those molecules work on cancer cells 
was elucidated [97]. In fact, nice data provided by Goswami et al. found that G0/G1 transition to  
S-phase of the cell cycle, must be promoted by a transitional peak of superoxide radicals. Furthermore, 
antioxidants that depurate free radicals are able to retain cell in a resting state [97–99]. Thus, thiol 
antioxidants perturb cellular proliferation by regulating the cell cycle and redox state in cells. On the 
contrary, oxidants production after release from NAC-induced G0/G1 arrest is associated with entry of 
murine embryonic fibroblast into S phase. 
Epidemiological studies have established a relationship between the incidence of cancer and 
consumption of certain types of food. The presence of antioxidants in diet has been directly related to 
lower incidence of cancer. In fact, chemoprevention has attracted the attention of oncologists and 
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molecular biologists to modulate carcinogenesis. A chemopreventive agent can inhibit carcinogenesis 
either by blocking initiation or by stopping or reversing promotion and progression. Animal and 
cellular models have been used to discover a new class of chemopreventive agents, including 
flavonoids, polyphenols or isothiocyanates [100]. The active components of dietary phytochemicals 
that most often appear to be protective against cancer are curcumin, genistein, resveratrol, diallyl 
sulfide, S-allyl cysteine, allicin, lycopene, capsaicin, diosgenin, 6-gingerol, ellagic acid, ursolic acid, 
silymarin, anethol, catechins, eugenol, isoeugenol, dithiolones, isothiocyanates, indole-3-carbinol, 
isoflavones, protease inhibitors, saponins, phytosterols, inositol hexaphosphate, vitamin C, d-limonenen, 
lutein, folic acid, beta carotene, selenium, vitamin E, flavonoids and dietary fiber [101]. Most of them 
display antioxidant properties in vitro but also affect multiple signaling pathways including 
transcription factors activation, like NFκB or AP-1, pro-oxidant or pro-inflammatory proteins, like 
COX-2 or iNOS or antioxidant proteins such as glutathione peroxidase (Table 1). 
Table 1. Natural antioxidants and their molecular targets implicated in cancer prevention. 
Bioactive Substance Source Tumor Molecular Pathways 1 
Curcumin 
Curcuma longa extract 
(turmeric) 
Ovarian, prostate, 
oral, 
gastrointestinal 
tumors 
NFKB1, AP-1, STAT1, STAT3, STAT5, 
CTNNB1, NFE2L2, IKBKB, EGFR, 
HER2, AKT, JNK, PKA, BCL2, 
BCL2L1, AR, TP53, GST, GPX, 
HMOX1, XOD, CCND1, ALOX5, 
PTGS2, NOS2 
Genistein 
(isoflavone) 
Soybeans, chickpea, 
kudzu root  
Pueraria labata radix; 
Cicer arietinum; 
Desmodium uncinatum 
Ovarian, prostate, 
colon, breast 
SLC2A1, ER, NFE2L2, autophagy, 
Multiple Tyrosine kinases, NFKB1, 
CASP12, CDKN1A, GPX 
Resveratrol 
Stilbene found in 
Fabaceae and  
Vitis vinifera 
Prostate, breast, 
colorectal 
PTGS2, NOS2, JNK, MEK, NFKB1, 
AP-1, CDKN1A, NFE2L2, TP53, BAX, 
caspases, BIRC5, CCND1, BCL2, 
BCL2L1, ALOX5, VEGF, AR, KLK3, 
HMOX1 
Diallyl sulfide,  
S-allyl cysteine, allicin 
(garlic compounds) 
Allium spp. 
Hepatoma cells, 
Hematologic 
tumors, colon, 
neuroblastoma 
IAP, Oxidative Stress generation, Cell 
Cycle arrest 
Lycopene, beta 
carotene 
Tomato, carrot, red 
fruits 
Prostate NFKB1 
Capsaicin 
Pepper, red chilis, 
paprika (Capsaicum 
spp.; Euphorbia spp.;  
C. annum; C. frutens) 
Colorectal, 
gastrointestinal, 
nasopharyngeal 
TRAIL, SP1, Cell cycle arrest, 
Apoptosis, NFKB1 
Diosgenin Discorea spp. 
Prostate, Lung, 
Colon 
HGF, TRAIL, MAPK1 
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Table 1. Cont. 
Bioactive Substance Source Tumor Molecular Pathways 1 
6-Gingerol 
Ginger, From  
Zingiber officinale 
Lung, 
Hepatocarcinoma 
cells 
Telomerase, NOS2, TNF1, APAF1, 
NFKB1, Caspases 
Ellagic acid Berries 
Oral, breast, 
Prostate, Colon 
CTNNB1, WNT, Apoptosis, AKT 
Ursolic acid 
Fruits, berries, aromatic 
herbs 
Breast, Melanoma NFKB1, BCL2, BCL2L1, BIRC5, TP53 
Silibinin (sylimarin) 
Milk thistle  
(Sylibum marianum) 
Lung, leukemia, 
gastric 
NFKB1, AP-1, MAPK, PTGS2, CCND1 
EGFR 
Anethole Anise, fennel Lung AKT, NFKB1, MMP2/9 
Catechins 
(flavonoids, 
flavanols) 
Tea (Camelia sinensis) Breast, prostate 
NFKP1, AP-1, JNK, PGST2, CCND1, 
HMOX1, TP53, IGF, BCL2, CDKN1A 
Eugenol, isoeugenol 
Cloves  
(Eugenia caryophyllus) 
Breast, cervix, 
colon 
NFKB1, PTGS2, NOS2 
Indole-3-carbinol 
(isothiocyanates) 
Cruciferous  
(Brassica spp.) 
Ovary, colon, 
lung, prostate 
Telomerase, SP1, Cell cycle arrest 
Saponins Soybean (Glycine max) 
Breast, skin, 
gastric 
PTGS2, NOS2, MAPK, NFKB1, MMP 
Vitamin C 
Many fruits and 
vegetables 
Colon, Ovary, 
prostate 
Oxidative stress, Cell cycle arrest, HIF 
d-Limonene Citrus oils 
Lymphoma, 
breast, gastric 
PTGS2, NOS2, ERK, caspases 
Lutein Tomato endometrial  
Folic acid 
Leafy vegetables, beans, 
fruits 
Colorectal cancer, 
neuroblastoma 
 
Selenium 
Esophageal, breast, lung 
prostate, gastrointestinal 
 
Co-factor of GPX, NFKB1, PTGS2, 
ER,TP53, CDKN1A  
Vitamin E, 
tocopherols 
Esophageal, breast, 
pancreas 
 
NFKB1, PTGS2, NOS2, VEGF, AKT, 
ERK 
1 Abbreviations used according to HGNC nomenclature: CTNNB1, β-catenin; survivin, BIRC5; 
NFE2L2, nuclear factor (erythroid-derived 2)-like 2 (Nrf2); IKBKB, IKK-Beta; BCL2L1, Bcl-XL; 
HMOX1, Heme Oxygenase 1 (HO-1); CCND1, Cyclin D1; ALOX5, 5-Lypooxygenase (5-LO), 
PTGS2, Cyclooxygenase-2 (COX2), SLC2A1, solute carrier family 2 (GLUT1); CDKN1A, 
P21/WAF1; KLK3, Prostate specific antigen (PSA). 
In that way, vitamins and other antioxidants present in fruit and vegetable-rich diets have been 
demonstrated to be powerful inhibitors of cell growth in vitro and in in vivo models. As an example, 
vitamin C, which is mostly present in a reduced form as ascorbic acid in human body, has been shown 
to inhibit the growth of several cancer cells by decreasing oxidative damage caused by carcinogens [102] 
or by promoting cell toxicity [103]. Similarly, vitamin E has been employed in several cellular 
contexts to inhibit proliferation or promote differentiation of cancer cells. Vitamin E inhibits cancer 
cell growth either by decreasing cell proliferation in estrogen dependent breast cancer cells [104] or by 
increasing FAS-mediated apoptosis [105]. Also, lycopene and apo-12'-lycopenal reduce the proliferation 
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of prostate cancer cells, in part, by inhibiting normal cell cycle progression and at low concentration 
and could synergistically inhibit the proliferation of colon cancer cells with eicosapentaenoic acid 
(EPA). The inhibitory mechanism was associated with suppression of phosphatidylinositol 3-kinase/Akt 
signaling pathway. Furthermore, treatment of lycopene and EPA also synergistically blocked the 
activation of downstream mTOR molecule [106]. 
Finally, several nutraceuticals including curcumin, resveratrol o genistein are able to reduce cancer 
cell proliferation by down-regulating the expression of cyclins or the activity of kinase dependent 
cyclins. In particular, cyclin D1 has been shown to be overexpressed in many cancer types including 
breast, esophagus, head and neck or prostate. In fact, resveratrol has been proved that exerts is anti-cancer 
effects by arresting cell cycle in colon adenocarcinoma cells, esophageal carcinoma cell, medulloblastoma 
cells, pancreatic carcinoma cells, human breast carcinoma, lung or leukemia cell lines. Resveratrol 
treatment caused an inhibition of cyclin D1 and cyclin-dependent kinase activity in all of them [101]. 
A direct relation between antioxidant properties of those compounds and their cell cycle inhibition is 
not clesar. However, considering that the transition from G0 to G1 is the only phase of the cell cycle 
which is not regulated by cyclin-dependent kinases, but rather by redox-dependent signaling pathways, 
expression of cyclin D1 represents a primary regulatory node for the dose-dependent effects of oxidants 
on the induction of cell growth. It was suggested that the expression of cyclin D1 represents a useful 
marker for assessing the integration of proliferative and growth inhibitory effects of oxidants on the 
redox-dependent signaling, and it seems clear when antioxidant compounds are employed to reduce 
proliferation [107]. 
5.2. Apoptosis Induced by Antioxidants 
Free radicals and antioxidants affect cancer cells behavior in many ways, depending on cell type or 
redox intracellular state. Since radical species can increase proliferation, halt cell cycle, or induce 
either senescence, apoptosis or necrosis, antioxidants might inhibit cancer cells growth in many different 
ways too. Activation of apoptosis might account for antioxidants’ inhibition of tumor progression 
since a balance between cell growth and death is necessary in tissue homeostasis. Tumor cells display 
several mechanisms of survival including inhibitory mechanisms of apoptosis. Several reports showed 
that activation of transcription factor NFκB promotes cell survival and proliferation and its 
downregulation sensitizes cells to apoptosis [108]. NFκB controls the expression of several genes 
including Bcl-2, Bcl-XL, cIAP, survivin, TRAF1 and TRAF2, all them known inhibitors of apoptosis. 
Thus, those compounds able to inhibit NFκB nuclear traslocation or binding activity are demonstrated 
to induce apoptosis in tumor cells. Also NFκB is a redox sensitive transcription factor that it is 
inhibited by the treatment with antioxidants, including vitamins, scavengers or metal chelators [109]. 
Considering this, much investigation about the role of antioxidants in promoting tumor cell death has 
been focused in their role as inhibitors of NFκB activation. In general, numerous publications support 
the role of phytochemicals, such as curcumin, resveratrol, flavopiridol, betulinic acid, ursolic acid, 
indole-3-carbinol, zerumbone, green tea polyphenols, among others, in reducing the expression of 
apoptosis suppressor proteins such as Bcl-2, Bcl-XL or survivin in cancer cells. Curcumin suppresses 
the constitutive expression of Bcl-2 and Bcl-XL in mantle cell lymphoma or multiple myeloma cell 
lines [110]. In addition, curcumin also activates caspase-7 and caspase-9 and induced polyadenosine-
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5'-dephosphate ribose polymerase (PARP) cleavage in both cell lines. Also, it has been reported that 
resveratrol exerts anti-cancer effects by promoting apoptosis in different types of tumor cells. Resveratrol 
inhibits metastatic breast cancer cell line, melanoma, pancreatic, esophageal adenocarcinoma or colon 
carcinoma cells apoptosis by decreasing Bcl-2 and Bcl-XL protein levels but also, by increasing 
apoptosis promoting protein Bax [111]. Also, green tea polyphenols are demonstrated that inhibit 
several types of tumors by increasing apoptosis. In prostate adenocarcinoma, EGCG induces 
stabilization of p53 and down-regulates NFκB which results in reducing Bcl-2 protein levels [112]. 
In summary, much of the chemopreventive activity of nutraceuticals is mediated by their role on 
redox sensitive transcription factors and upregulation of apoptosis pathways. In general, the 
constitutive activation of those AP-1 or NFκB, transcription factors is associated with a survival 
phenotype of cancer cells. In addition, anti-cancer treatments, including gamma-radiation, cytokines or 
chemotherapy, by increasing ROS inside cells, can activate redox-sensitive transcription factors that 
finally are able to promote the activation of survival signals that inhibit the end point search by tumor 
treatment. In that way, cancer cells develop those mechanisms to escape therapy and searching for 
compounds able to inhibit those mechanisms without compromising its effectiveness is of interest to 
oncologists. Consequently, antioxidants can be promising molecules to employ alone or in 
combination of conventional anti-cancer treatments. However, are those antioxidants able to 
discriminate between normal and tumor cells, are those molecules compromising effectiveness of 
treatment and many more questions are still in the mind of cancer biologists and physicians. 
5.3. Human Studies with Antioxidants 
Interestingly, several clinical trials have increased confusion about this topic. A good review of 
strong and weak aspects of those clinical trials has been made in a systematic review and meta-analysis 
conducted by Bardia et al. [113]. By using multiple electronic databases they search for randomized 
clinical trials to estimate the association between antioxidant treatment and cancer incidence and 
mortality. Although their study concludes that beta carotene supplementation appeared to increase 
cancer incidence among smokers, while vitamin E has no effect and selenium might have antitumor 
properties, it has several limitations that even the authors considered. The heterogeneous group of 
antioxidants, different combinations and dosages but also, some limitations of the design of the trial or 
the interpretation of results are important issues to be considered. In this regard, the expert opinion of 
Halliwell published in The Lancet in 2000 [26] about the use of antioxidants for the treatment of 
human diseases might be considered. In fact, some factors can help to understand contradictory results 
in cancer trials too. The protective effect of diet in cancer is not equivalent to a protective effect of 
antioxidants, and also, a good antioxidant might be a reducing agent depending on the environment in 
which it is working. Human cells are in a reduced state, but some degree of localized oxidation is 
needed. Thus, antioxidants can sometimes work differently depending on the redox situation inside 
cells. Similarly, in cell culture models we can find a molecule that can be a powerful antioxidant or a  
pro-oxidant agent, depending on cellular context. That is the case of vitamin C, which prevents the 
damage of the herbicide paraquat when it is employed prior to exposition to the toxic agent but it can 
even aggravate paraquat toxicity when it is given afterwards. Thus, the more reducing an antioxidant is 
the more problems it might cause. The study of precise molecular mechanisms is necessary to develop 
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adequate protocols, the use of antioxidants in anti-cancer treatment needs a pro study of the role of 
antioxidants and free radicals in cancer biology in the context of in vivo experiments. Antioxidants 
might also inhibit the oxidant signaling mechanisms that cells use to adapt to free-radical insults, so a 
participation of endogenous antioxidant defenses in tumor survival is an important issue to take  
into consideration. 
6. Redox-Related Enzymes and Cancer 
6.1. Superoxide Dismutases and Cancer 
Antioxidant enzymes that remove the intermediates of oxygen reduction, in particular superoxide 
dismutases (SOD), catalase and glutathione peroxidase (GPX) act by preventing oxidative damage 
together with noncatalytic antioxidants, including non-thiol compounds as vitamins or polyphenols 
and sulfur-containing compounds, like glutathione (GSH) and thioredoxin (Trx) [114]. Consequently, 
two different types of oxidative alterations, ROS overproduction or physiological mild oxidative 
unbalances are responsible for regulatory processes in cancer cells; therefore, as mentioned above 
antioxidants can play multiple roles in cancer initiation, promotion or progression. 
Among major antioxidant enzymes inside cells are, in addition to glutathione cycle proteins, 
superoxide dismutase enzymes. There are two major forms, mitochondrial or manganese-containing 
SOD (MnSOD/SOD2) and cytosolic or copper-zinc containing SOD (CuZnSOD/SOD1). In particular, 
MnSOD KO mice do not survive long after birth due to severe lung damage and neurodegeneration. It 
was first observed that UV radiation stimulates MnSOD expression but also, that it mediated gene 
expression in radiation-induced adaptive responses [34]. Huang et al. reported that 2-methoxyestradiol 
(2-ME), an estrogen derivative that lacks the ability to bind to the estrogen receptor, kills human 
leukemia cells by promoting apoptosis. This apoptosis is mediated by inhibition of CuZnSOD which in 
turn promotes accumulation of O2−. In addition, overexpression of CuZnSOD reverted sensitivity to  
2-ME but treatment with oligonucleotides against SOD were more sensitivity to 2-ME [115]. 
Differences in antioxidant status between normal and tumor cells have been found. Generally, lower 
levels of antioxidant enzymes have been found in tumor cells in early progression states. Thus, as an 
example, the expression of three major antioxidant enzymes, CuZnSOD, MnSOD and catalase were 
altered in human prostate carcinoma [116] which has been associated with higher sensibility to DNA 
damage cause by ROS. CuZnSOD, MnSOD and catalase had lower expression in high grade prostatic 
intraepithelial neoplasia (PIN) and prostate carcinoma than in benign epithelium. In the same way, 
cytosolic glutathione S-transferases (GSTs) which are a superfamily of enzymes that protect normal 
cells by catalyzing conjugation reactions of electrophilic compounds to glutathione, tends to decrease 
in some sort of cancer cells. Thus, it promotes the pro-oxidant environment necessary for progression, 
as it occurs in renal cell carcinoma growth [117]. Moreover, GST polymorphism are commonly found 
in other types of cancer, where its activity is compromised, including ovarian cancer or prostate [118]. 
Glutathione transferase GSTM1-null genotype may increase risk for tobacco related cancer through the 
impairment of polycyclic aromatic hydrocarbons detoxification. 
In general, an increase in oxidative and decrease in antioxidant status has been observed in several 
types of tumors [119]. In addition, the overexpression of antioxidant enzymes has been an efficient strategy 
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to reduce proliferation of normal but also cancer cells. MnSOD has been considered a tumor suppressor 
gene in several human and murine tumor cell lines. Thus, MnSOD overexpresion reduces the proliferation 
of melanoma, prostate, pancreatic, breast, oral carcinoma and glioma cellular growth [120–122]. Also, 
overexpression of CuZnSOD, reduces the growth of glioma [123]. The decreased rate of tumor cell 
growth was correlated with the enzyme activity ratio of CuZnSOD:GPx. Glioma cells that stably 
overexpressed CuZnSOD demonstrated additional suppressive effects on the malignant phenotype and 
changes in the cellular redox status, attributable to the accumulation of hydrogen peroxide or other 
hydroperoxides and, a possible reason to explain the suppression of tumor growth observed in 
CuZnSOD-overexpressing cells. 
Many strategies of tumor cells to survive against anticancer treatments are related with the 
activation of NFκB activity. NFκB regulates, among others, the expression of some antioxidant 
enzymes including MnSOD. NFκB is also closely linked to MnSOD expression induced by phorbol 
myristate acetate, cytokine, and serum starvation leading to antiapoptotic responses to TNFα [124]. 
The role of MnSOD in cellular survival is clear, since downregulation of MnSOD compromises cell 
viability in several contexts. Chronic exposure of cells to ionizing radiation (IR) induces an adaptive 
response that results in enhanced tolerance to the subsequent cytotoxicity of IR and by using MnSOD 
knockout mice (Sod2−/−), MnSOD was shown to be essential in protecting against ROS-induced injury 
during O2 metabolism. Moreover, endogenous SOD activity is also involved in the resistance of 
Wilms' tumors to chemotherapeutic agents and in protecting human leukemic and cancer cells from 
radiation. The expression of MnSOD causes significant alterations in the malignant phenotype as well 
as inhibition of tumor growth in vivo. It was demonstrated that in MCF-7 cells treated with 
fractionated ionizing radiation or overexpressing MnSOD showed significant radioresistance, and 
endogenous MnSOD was induced in irradiated wild-type MCF-7 cells. A causal relationship between 
MnSOD expression, increased radiation resistance, and increased expression of stress-responsive 
genes and also, the inhibition of NFkB-mediated transcriptional activity with mutant IkB 
radiosensitized MCF7 cells treated with fractionated ionizing radiation as well as reducing the 
transcription of MnSOD [34]. Actually, our own results indicate that overexpression of MnSOD in 
prostate cancer cells is a common marker of neuroendocrine phenotype which is associated to a higher 
resistance to hormonal control and survival. That targeting antioxidant defense may be a promising 
approach to the selective killing of cancer cells. Mechanism based on combinations of cancer 
inhibitors with free-radical-producing agents may have clinical application [114,125]. 
Based on evidence, a unique anticancer strategy for treatment of tumors named “oxidation therapy” 
has been proposed involving inducing cytotoxic “oxystress”. This means that, mainly by using two 
methods, namely: (i) inducing the generation of ROS directly in solid tumors and (ii) inhibiting the 
antioxidant enzyme (defense) system of tumor cells, it would be feasible to promote cancer cell  
death [126,127]. Since the late sixties, the use of H2O2 for treating tumors in animal tumor models was 
assayed by injection in tumoral tissues or by administration into the circulation. Although, no 
satisfactory results were observed, these were the pioneering studies in using ROS as anticancer 
therapy. Side effects due to loss of selectivity were major problems. Today the anticancer potential of 
these agents is still under investigation, and it is intended to be solved by including macromolecular 
drugs, polymeric micelles or nanoparticles. In addition, downregulation or inhibition of antioxidant 
enzymes are expected to become anticancer strategies in the future. Heme oxygenase 1 (HO-1) [126] 
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and MnSOD [115] play a central role in the defense in healthy tissues and become much important in 
tumors for defending against ROS and ROS-generating antitumor agents. The inhibition of HO-1 (see 
below) or SOD has been also proposed as an effective method for killing tumor cells. Then, antitumor 
strategies based on “oxidation therapy” might be a promising approach for clinical maneuver of tumors 
which are still resistant to conventional treatments. 
6.2. A New Role of MnSOD in Cancer: Cell Differentiation 
Some years ago, our laboratory started a new research line with the intention of using a 
combination of radiotherapy with the endogenous antioxidant melatonin to induce cell death in 
prostate cancer cells. Based on the rationale that, years before, it had been demonstrated that melatonin 
works as an efficient antioxidant and also, that melatonin inhibits NFκB activation after gamma 
irradiation or cytokine treatment [128], we studied its role in tumor growth and promotion of 
apoptosis. Androgen-independent prostate cancer cells are highly resistant to chemotherapy or 
radiation because they show a constitutive activation of NFκB and high levels of antiapoptotic proteins 
like Bcl-2 and survivin. Melatonin had been shown previously to reduce proliferation through its 
antioxidant activity [129], but its role in inducing apoptosis in cancer cells had not been explored at 
that time. Surprisingly, we found that this molecule was able to reduce proliferation, to inhibit 
radiation or TNFα-induced NFκB activation, but it was unable to promote apoptosis [125,130]. 
Moreover, cells treated with melatonin showed a neuroendocrine phenotype similar to other treatments 
described previously in the literature. The phenotype of neuroendocrine cells favors survival of 
prostate cancer cells and it is activated after several situations of cellular stress, including androgen 
withdrawal, IL-6 treatment or increment of cAMP intracellular levels. That surprise, lead our research 
to study the role of antioxidant defenses in prostate cancer cells survival. Years before, we also had 
found that melatonin regulates glutathione content and MnSOD, catalase or GPX mRNA, protein or 
activity [131]. Finally, we concluded that melatonin, and perhaps other antioxidants such as silibinin 
which also induce differentiation of prostate cancer cells, which do not increase apoptosis, but still 
inhibit NFκB activation, do not increase cell death because they are increasing endogenous 
antioxidants such as antioxidant enzymes or GSH [130]. Later on, we demonstrated that 
overexpression of MnSOD is a common mechanism during neuroendocrine differentiation in prostate 
cancer cells and it might be responsible for treatment resistance and cellular survival [132]. 
In that way, tumor cells develop many ways to escape cell death caused by cancer treatments. The 
design of cancer chemotherapy which avoids those mechanisms implicated in cancer cell survival is of 
interest. Resistance to treatment results from several factors, including individual variations in patients 
or somatic genetic differences in tumors. As therapy becomes more and more effective, acquired 
resistance is also a common event. The major players in cancer resistance to therapy is the expression 
of one or more energy-dependent transporters, insensitivity to drug-induced apoptosis, as mentioned 
above, or induction of drug-detoxifying mechanisms [133]. In those cases of resistance, the employment 
of multiple drugs with different mechanisms of entry into cells and different cellular targets allow for 
more effective chemotherapy and higher response. However, too often, cells express mechanisms that 
confer simultaneous resistance to many different structurally and functionally unrelated drugs. This 
phenomenon is known as multidrug resistance and results from changes that limit accumulation of 
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drugs within cells by limiting uptake, enhancing efflux or affecting membrane lipids [134]. Once 
mechanisms of drug resistance were discovered, numerous strategies have been tested. Among others, 
targeting antiapoptotic proteins using antisense oligonucleotides strategies, including BCL-2, BCL-XL, 
or by enhancing IAPs activity by employing naturally occurring peptides, modulating methylation 
status of tumor suppressors or genes that affect drug sensitivity, are explored to favor drug sensitivity. 
In relation to antioxidant status, depletion of GSH to modulate drug resistance has also been 
considered [135]. 
6.3. Glutathione and Cancer 
GSH is a cysteine-containing peptide that is synthesized by γ-glutamyl cysteine synthase (γ-GCS) in 
two steps. Intracellular concentration of GSH exceeds 10mM in some cells and it has been implicated 
in resistance to several chemotherapeutic agents. Increased levels of GSH are involved in resistance to 
platinum compounds in human ovarian carcinoma cells [136] but also as contributor to anthracycline 
resistance favoring its metabolism [137]. On the other side, depletion of GSH has also been demonstrated 
to increase the sensitivity to arsenic trioxide in multiple myeloma cells. Thus, retroviral vector-mediated 
overexpression of MRP1 and γ-GCS resulted in higher GSH levels and a greater level of resistance to 
sodium arsenite compared to overexpression of either MRP1 or γ-GCS alone. Then, GSH is an important 
cofactor of MRP1 conferring resistance to arsenical compounds [138]. Given that, three different 
strategies have been followed to deplete intracellular glutathione to increase sensitivity to therapeutic 
drugs. First, the employment of L-buthionine-(S,R)-sulfoxime (BSO), a potent inhibitor of γ-GCS has 
been demonstrated to deplete intracellular concentrations of GSH and enhance the sensitivity to 
platinum-containing compounds, alkylating agents, anthracyclines and arsenic trioxide [139]. Second, 
the use of a hammerhead ribozyme against γ-GCS mRNA to downregulate its levels specifically [140] 
and reversed resistance to cisplatin, doxorubicin and etoposide in HCT-8 cells colon cancer cells. 
Finally, a third strategy targeted c-Jun expression. Increased levels of GSH and γ-GCS were associated 
with a stable increase of c-jun expression and c-Jun binding to AP-1 transcription factor. By using, a 
20-mer c-jun phosphorotionate ASO, a decrease of the steady-state levels of c-jun mRNA and protein 
was performed and a reduction in γ-GCS affecting GSH intracellular levels [136]. 
6.4. Nitric Oxide and Peroxynitrite 
Nitric oxide (NO) has been one of those free radicals to be included in the list of cell signaling 
regulators in both animals and plants; even bacteria can sense very low concentrations of NO. As one 
of its discoverers has mentioned, the fact that NO is a free radical and can act as an intracellular 
messenger modulating enzymes such as certain isoforms of guanylate cyclase (GC), although now 
assumed, was initially viewed skeptically [141]. NO is produced from L-arginine by any of the three 
isoforms of NOS. NO then binds to the prosthetic heme group of NO-sensitive GC [142], which in 
turn activates this enzyme resulting in an increase in cGMP levels. This events lead to different cell 
responses including smooth muscle relaxation-essential for endothelium regulation- or neurotransmission. 
However, it is now widely accepted that, depending on the intracellular concentrations of NO reached, 
it may exert a variety of intracellular actions ranging from promoting cell survival, increasing cell 
proliferation or even inducing cell death [143]. 
Cancers 2012, 4                                       
 
 
462
Additionally, NO-derived metabolites regulate cell physiology at the protein level by formation of 
S-nitrosothiol, causing the so called S-nitrosylation of cysteine residues. This modification would act 
in a NO-mediated, cGMP-independent pathway, resulting in modulation of many key cell regulators 
including [144–146]. 
In addition to S-nitrosothiol, other NO-derived free radical species collectively called RNS are also 
formed, e.g., nitrosoium ioins (NO+), dinitrosyl-iron complexes and the combination of NO with O2•−, 
peroxynitrite (ONOO−). Peroxynitrite accounts for a rapid depletion of sulfhydryl groups and 
antioxidants, oxidation of lipids, DNA strand breakage, nitration and deamination of DNA bases and 
nitration of aromatic amino acids in proteins [147,148]. The most studied by far is the reaction with 
tyrosine residues to form 3-nitrotyrosine, leading in some cases to enzyme inactivation or to interference 
with signal transduction [149]. There is growing evidence about the potential role of 3-nitrotyrosine, at 
least as a biomarker, in cancer, but it still requires further research [150,151]. 
6.5. Xanthine Oxidase and ROS Production in Cancer 
During purine catabolism, Hypoxanthine-Xanthine Oxidase (or Oxidoreductase, EC 1.17.3.2) 
(XOR) first catalyzes hydroxylation of hypoxanthine to xanthine and subsequently of xanthine to 
urate, giving rise to H2O2 as a byproduct. Since uric acid and its oxidation product allantoin may act as 
a free radical scavenger, XOR has consequently a pivotal role, either as an enzymatic antioxidant 
mechanism [152] or as a regulator of cellular redox status [153]. More recently it has been shown a 
role of XOR in innate immunity, as a mediator of infection and inflammation through its interaction 
with NF-κB and AP-1; furthermore it has also a role in ROS production during phagocytosis [154]. 
Nevertheless, several lines of research have shown the implication of XOR in different pathological 
situations through associated overproduction of ROS/RNS [155]. XOR has a role in ROS production 
during myocardial ischemia/reperfusion injury [156]. In this way microvascular endothelial cells 
preincubation with XOR increase adhesion of colon carcinoma cells [157]. Similarly, Griguer et al. 
have shown that XOR is one of the key enzymes producing ROS that stabilizes HIF-1α in cancer  
cells [158]. Interestingly, based on these and other evidence, some XOR inhibitors are under 
investigation for anti-cancer treatment [127,159]. 
6.6. Heme-Oxygenase 1 
Heme-Oxygenase 1 (EC 1.14.99.3) (HO-1) is an inducible enzyme that catalyzes the rate limiting 
reaction in heme degradation to form CO, biliverdin and ferrous iron. While CO may serve as a second 
messenger in inflammation, proliferation and apoptosis [160], biliverdin is subsequently reduced to 
bilirubin and both of them have antioxidant properties. Finally ferrous iron induces the expression of 
ferritin, an important iron-storage protein. It is considered an antioxidant enzyme with anti-inflammatory, 
anti-apoptotic and anti-viral properties. Its expression remains basal under normal conditions but it is 
highly inducible as a response to several stimuli protecting cells against oxidative and inflammatory 
injuries. HO-1 deficiency has been reported in patients who died early with severe inflammatory 
symptoms [161,162], therefore revealing a key immunomodulatory role of HO-1. As it has been 
suggested by a body of evidence and epidemiological studies, chronic inflammation accounts for one third 
of all diagnosed cancers [163–166]. HO-1’s role in cancer displays a debate between the beneficial 
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upregulation and subsequent protective role in spontaneous or induced autoimmune diseases and other 
chronic inflammatory pathologies against its harmful upregulation in tumor cells where the enzyme 
might even promote tumor growth by lowering the immune response. Recently, HO-1 upregulation has 
been associated to poor prognosis in lung cancer [167]. HO-1 also appears as a key upregulated gene in 
neuroblastoma [168], pancreatic [169], gastrointestinal [170] or colon cancer [171]. Targeting HO-1 
with selective inhibitors has therefore become an important strategy in oncology. 
7. Conclusions 
The fact that free radicals participate in tumor initiation by promoting DNA damage has been long 
accepted, but that same free radicals might take on an important role in signaling pathways has more 
recently been accepted (Figure 1). 
Figure 1. Oxidative species play an important role in cellular signaling through  
post-trascriptional modifications of important proteins. Those proteins modified by 
oxidative modifications show an important role in cellular process such as cell proliferation 
and survival. Both, deregulation of cell growth and death are the main aspects to explain 
cancer progression and promotion. ROS/RNS control by antioxidants has been efficiently 
proven to reduce tumor growth and progression both in cellular and animal models but a 
wide spectrum of biological player modify by oxidative species makes difficult to apply 
these knowledge to the clinical practice. 
 
The role of oxidative species as mediators of growth factors in several signaling pathways now 
seems clear, but their role in tumor progression it is still uncertain. It a role of oxidative species, such 
H2O2, in the activation of ASK-1 MAPK is also clear, but the participation of downstream cascades 
needs to be explored. Also, nuclear translocation and DNA binding of transcription factors, mainly 
AP-1 or NFκB, has been demonstrated, but their role in compromising survival of cancer cells through 
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their activation is still unknown. In addition to other well-known mechanisms of drug resistance, 
adaptive mechanisms which imply overexpression of antioxidant enzymes have been demonstrated 
after irradiation in different types of tumor cells. 
In addition to other principal players inside cells, high reactive molecules such as free radicals 
which are produced by cell metabolism, need to be carefully regulated to allow proper functioning of 
cells and a deregulation of those molecules and downstream signaling pathways might be a cause of 
pathological situations. Preliminary data, by using antioxidants in vivo clinical trials, have been 
contradictory respect to the use of these molecules as anti-cancer strategies, but abundant in vitro and 
in vivo evidence strongly support the role of free radicals, antioxidants and antioxidant enzymes in 
cancer initiation or progression. An effort should be made to find out the missing information in trials 
or aspects still unknown in the biology of tumor cells which might allow researchers and oncologists 
to find a better way to understand the scenario and the role that oxidative-mediate signaling plays in 
the disease. 
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